These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 3189043

  • 21. IL-10 regulates murine lupus.
    Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, McNiff J, Madaio MP, Craft J.
    J Immunol; 2002 Aug 15; 169(4):2148-55. PubMed ID: 12165544
    [Abstract] [Full Text] [Related]

  • 22. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
    Yan SX, Deng XM, Wang QT, Sun XJ, Wei W.
    Acta Pharmacol Sin; 2015 Nov 15; 36(11):1367-76. PubMed ID: 26456588
    [Abstract] [Full Text] [Related]

  • 23. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice.
    Swenson J, Olgun S, Radjavi A, Kaur T, Reilly CM.
    Eur J Pharmacol; 2007 Jul 12; 567(1-2):67-76. PubMed ID: 17490635
    [Abstract] [Full Text] [Related]

  • 24. Iron status alters murine systemic lupus erythematosus.
    Leiter LM, Reuhl KR, Racis SP, Sherman AR.
    J Nutr; 1995 Mar 12; 125(3):474-84. PubMed ID: 7876923
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the Japanese-Chinese herbal medicine, kampo, for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice.
    Kanauchi H, Imamura S, Takigawa M, Furukawa F.
    J Dermatol; 1994 Dec 12; 21(12):935-9. PubMed ID: 7868765
    [Abstract] [Full Text] [Related]

  • 26. Deoxyspergualin therapy in autoimmune MRL/1pr mice suffering advanced lupus-like disease.
    Nemoto K, Mae T, Sugawara Y, Hayashi M, Abe F, Takeuchi T.
    J Antibiot (Tokyo); 1990 Dec 12; 43(12):1590-6. PubMed ID: 2276976
    [Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.
    Hecht M, Müller M, Lohmann-Matthes ML, Emmendörffer A.
    J Leukoc Biol; 1995 Feb 12; 57(2):242-9. PubMed ID: 7852838
    [Abstract] [Full Text] [Related]

  • 28. Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.
    Tada Y, Kondo S, Aoki S, Koarada S, Inoue H, Suematsu R, Ohta A, Mak TW, Nagasawa K.
    Arthritis Rheum; 2011 Mar 12; 63(3):738-48. PubMed ID: 21305501
    [Abstract] [Full Text] [Related]

  • 29. Treatment with danazol and plasma glucagon concentration.
    Williams G, Lofts F, Fuessl H, Bloom S.
    Br Med J (Clin Res Ed); 1985 Oct 26; 291(6503):1155-6. PubMed ID: 3931833
    [Abstract] [Full Text] [Related]

  • 30. Effect of danazol on lupus-erythematosus-like disease in hereditary angioneurotic oedema.
    Donaldson VH, Hess EV.
    Lancet; 1980 Nov 22; 2(8204):1145. PubMed ID: 6107762
    [No Abstract] [Full Text] [Related]

  • 31. Hyperglucagonaemia and treatment with danazol for systemic lupus erythematosus.
    David J.
    Br Med J (Clin Res Ed); 1985 Oct 26; 291(6503):1170-1. PubMed ID: 3931840
    [No Abstract] [Full Text] [Related]

  • 32. Cd72(c) is a modifier gene that regulates Fas(lpr)-induced autoimmune disease.
    Xu M, Hou R, Sato-Hayashizaki A, Man R, Zhu C, Wakabayashi C, Hirose S, Adachi T, Tsubata T.
    J Immunol; 2013 Jun 01; 190(11):5436-45. PubMed ID: 23616572
    [Abstract] [Full Text] [Related]

  • 33. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice.
    Wu WM, Suen JL, Lin BF, Chiang BL.
    Immunology; 2000 May 01; 100(1):110-8. PubMed ID: 10809966
    [Abstract] [Full Text] [Related]

  • 34. Splenic norepinephrine is decreased in MRL-lpr/lpr mice.
    Breneman SM, Moynihan JA, Grota LJ, Felten DL, Felten SY.
    Brain Behav Immun; 1993 Jun 01; 7(2):135-43. PubMed ID: 8347895
    [Abstract] [Full Text] [Related]

  • 35. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):230-7. PubMed ID: 23712004
    [Abstract] [Full Text] [Related]

  • 36. Reversal of lupus-erythematosus-like disease with danazol.
    Masse R, Youinou P, Dorval JC, Cledes J.
    Lancet; 1980 Sep 20; 2(8195 pt 1):651. PubMed ID: 6107447
    [No Abstract] [Full Text] [Related]

  • 37. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
    Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S.
    Nephron; 1993 Sep 20; 64(3):471-5. PubMed ID: 7688103
    [Abstract] [Full Text] [Related]

  • 38. Autoimmune abnormality affects ovulation and oocyte-pick-up in MRL/MpJ-Fas lpr/lpr mice.
    Hosotani M, Ichii O, Nakamura T, Kanazawa SO, Elewa YHA, Kon Y.
    Lupus; 2018 Jan 20; 27(1):82-94. PubMed ID: 28566018
    [Abstract] [Full Text] [Related]

  • 39. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice.
    Komori H, Furukawa H, Mori S, Ito MR, Terada M, Zhang MC, Ishii N, Sakuma N, Nose M, Ono M.
    J Immunol; 2006 Jan 01; 176(1):395-400. PubMed ID: 16365433
    [Abstract] [Full Text] [Related]

  • 40. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice.
    Zhang XK, Gallant S, Molano I, Moussa OM, Ruiz P, Spyropoulos DD, Watson DK, Gilkeson G.
    J Immunol; 2004 Nov 15; 173(10):6481-9. PubMed ID: 15528390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.